title: A possible role of VEGF in osteolytic bone metastasis of hepatocellular carcinoma.
abstract: The incidence of bone metastasis was around 13% in 404 patients with hepatocellular carcinoma (HCC) who underwent treatment at the National Kyushu Cancer Center between 1988-97, which is a high value among various cancers. This is, in part, due to the prolonged survival time of HCC patients in recent years. Serum vascular endothelial growth factor (VEGF) levels were significantly elevated in HCC patients with bone metastases as compared to those in patients with liver cirrhosis/chronic hepatitis and HCC patients without bone metastasis. VEGF was positively stained in both the primary lesion and bone metastasis of HCC by immunohistochemistry. In the process of bone metastasis, an increase in bone resorption is a crucial step prior to invasion of the bone. VEGF, the most important angiogenic factor, has been shown to stimulate bone resorption through its effects on osteoclasts. Thus, HCC cells reach the bone marrow space, and then secrete VEGF which facilitates osteolytic bone metastasis. VEGF may also facilitate tumor growth in the bone by acting as an angiogenic factor once invasion of the bone is complete. This might be another reason for the high incidence of bone metastasis in HCC.
authors.affiliation: Division of Biochemistry, National Kyushu Cancer Center Research Institute, Fukuoka, Japan.
authors.forename: H
authors.initials: H
authors.lastname: Iguchi
authors.forename: M
authors.initials: M
authors.lastname: Yokota
authors.forename: M
authors.initials: M
authors.lastname: Fukutomi
authors.forename: K
authors.initials: K
authors.lastname: Uchimura
authors.forename: H
authors.initials: H
authors.lastname: Yonemasu
authors.forename: Y
authors.initials: Y
authors.lastname: Hachitanda
authors.forename: Y
authors.initials: Y
authors.lastname: Nakao
authors.forename: Y
authors.initials: Y
authors.lastname: Tanaka
authors.forename: T
authors.initials: T
authors.lastname: Sumii
authors.forename: A
authors.initials: A
authors.lastname: Funakoshi
mesh_terms: D014408:Biomarkers, Tumor; D001859:Bone Neoplasms / Q000097:blood* / Q000556:secondary*; D006528:Carcinoma, Hepatocellular / Q000097:blood* / Q000556:secondary*; D016022:Case-Control Studies; D024042:Collagen Type I; D016228:Endothelial Growth Factors / Q000097:blood*; D006521:Hepatitis, Chronic / Q000097:blood / Q000473:pathology; D006801:Humans; D007124:Immunoenzyme Techniques; D036341:Intercellular Signaling Peptides and Proteins / Q000097:blood*; D008103:Liver Cirrhosis / Q000097:blood / Q000473:pathology; D008113:Liver Neoplasms / Q000473:pathology*; D008222:Lymphokines / Q000097:blood*; D010014:Osteolysis; D010446:Peptide Fragments / Q000097:blood; D010455:Peptides; D011347:Procollagen / Q000097:blood; D011379:Prognosis; D015996:Survival Rate; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors
chemical_list: D014408:Biomarkers, Tumor; D024042:Collagen Type I; D016228:Endothelial Growth Factors; D036341:Intercellular Signaling Peptides and Proteins; D008222:Lymphokines; D010446:Peptide Fragments; D010455:Peptides; D011347:Procollagen; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors; C052929:collagen type I trimeric cross-linked peptide